BRAF and thyroid cancer: The model has demonstrated in vivo the genetic requirement for Twist expression downstream of BRAFV600E, as ablation of twist3 by CRISPR-Cas9 suppressed BRAF-mediated oncogenesis.49 The in vivo validation of targeted molecular therapies for the treatment of thyroid cancer demonstrates the applicability of the zebrafish system to precision oncology approaches.